Glenmark recalls 114 batches of potassium chloride capsules
26 Jun 2024
Glenmark Pharmaceuticals has announced a voluntary recall of 114 batches of its 750 mg potassium chloride extended-release capsules due to failed dissolution tests.
This defect could result in hyperkalemia, a potentially life-threatening increase in potassium levels, especially in patients with conditions like hypertension or renal dysfunction. The affected products were manufactured at a facility in Madhya Pradesh, India and distributed nationwide in the U.S.
Hypokalemia, the condition treated by these capsules, refers to a lower-than-normal level of potassium in the bloodstream. Potassium is vital for many bodily functions, including the regulation of heart and muscle function, and the transmission of nerve signals. Insufficient potassium can cause symptoms such as weakness, fatigue, muscle cramps, and irregular heartbeats, and in severe cases, it can be life-threatening due to the potential impact on heart rhythm.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.